The global prevalence of HIV, hepatitis, Ebola, and other viral diseases is driving significant market growth in the antiviral drugs market. Furthermore, growing viral disease awareness initiatives and an increasing geriatric population base susceptible to viral diseases will contribute to an increase in demand for antiviral drugs. Moreover, increasing advancements in antiviral drugs, such as proteolysis targeting chimera mechanism, targeted covalent inhibitor mechanism, and others to improve drug efficacy, will drive the antiviral drugs market
LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antiviral Drugs Market Insights report provides the current and forecast market analysis, individual leading antiviral drugs companies' market shares, challenges, antiviral drugs market drivers, barriers, and trends, and key antiviral drugs companies in the market.
Key Takeaways from the Antiviral Drugs Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global antiviral drugs market during the forecast period.
- Notable antiviral drugs companies such as AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and several others are currently operating in the antiviral drugs market.
- In January 2023, China's medical products regulator approved two more domestically developed antiviral drugs as the country braces for a possible wave of post-Lunar New Year Covid-19 infections.
- In January 2023, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the publication of a paper titled "Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus" in the journal Antiviral Research.
- In December 2022, the FDA approved lenacapavir (Sunlenca) as a first-in-class, twice-yearly treatment option for heavily treated adults with multidrug-resistant HIV-1.
- In January 2022, Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup for the treatment of adults suffering from COVID-19 in the country.
- In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product will be available at affordable prices at retail chemists, pharmacy chains, hospitals, and online stores.
To read more about the latest highlights related to the antiviral drugs market, get a snapshot of the key highlights entailed in the Global Antiviral Drugs Market Report
Antiviral Drugs Overview
The rise in viral infections and respiratory syncytial virus epidemics in recent years has been attributed to changing environmental conditions. Other factors such as increased human mobility, increased trade and tourism, and shifting geographic distributions of disease vectors all contribute to the rapid spread of viral infectious diseases. Antiviral medications reduce the ability of viruses to spread via physical contact or aerosols. These medications shorten the duration of flu symptoms and are recommended for the future treatment and prevention of influenza-like symptoms and viral pneumonia. The medicines may also reduce the risk of respiratory complications. Oseltamivir phosphate (Tamiflu), Baloxavir, and zanamivir (Relenza) are some of the most commonly prescribed Food and Drug Administration (FDA)-approved antiviral medications recommended by the Centers for Disease Control and Prevention (CDC) to treat seasonal flu.
Antiviral Drugs Market Insights
North America dominated the global antiviral drug market in 2021 and will continue to do so during the forecast period of 2022-2027. This can be attributed to the increasing demand for antiviral drugs in the region due to the rising prevalence of many viral and infectious diseases, the growing geriatric patient pool suffering from viral diseases, the increasing initiatives for viral disease awareness, and others.
Furthermore, the region's antiviral drug launches, regulatory approvals, and other activities, such as acquisitions and agreements, will lead to increased market demand. For instance, in December 2022, the FDA approved lenacapavir (Sunlenca) as a first-in-class, twice-yearly treatment option for heavily treated adults with multidrug-resistant HIV-1. Lenacapavir works through a multi-stage mechanism of action "distinguishable from other currently approved classes of antiviral agents.
To know more about why North America is leading the market growth in the antiviral drugs market, get a snapshot of the Antiviral Drugs Market Outlook
Antiviral Drugs Market Dynamics
According to the World Health Organization (WHO) 2022, nearly 38.4 million people worldwide were infected with HIV in 2021. According to the source, nearly 36.7 million were adults (aged 15 and up), and approximately 1.7 million were children (aged less than 15). As a result, the rising prevalence of HIV infection and increased public awareness of the disease will drive up demand for antiviral drugs used to treat HIV infection.
Furthermore, expanding product launches and approvals around the world, the presence of a robust number of drugs in the pipeline, and strategic activities by key players to increase manufacturing and research for antiviral drugs will all help to boost the antiviral drugs market.
Moreover, advances in molecular biology are spurring drug development, coinciding with the increased use of nucleoside and nucleotide analogs as first-line antivirals. Many small molecule-based anti-viral drugs are expected to receive product approvals in the future, propelling the antiviral drugs market growth to unprecedented levels during the forecast period, according to the market's current development pipeline.
However, the emergence of antiviral drug resistance, antiviral drug side effects, the high cost of therapy, and the stringent regulatory approval process may prove to be impediments to antiviral drugs market growth.
Additionally, during the COVID-19 pandemic, antiviral drugs were used to prevent the spread of the SARS-CoV-2 virus and other infectious agents, which boosted the antiviral drugs market. Although the market suffered during the initial lockdown stage due to strict lockdown restrictions and disruption in manufacturing and supply chains. However, as the demand for antiviral drugs increased, the market's key players accelerated their production. Many key players engaged in antiviral drug strategic decisions, investments, and research and development activities, resulting in increased demand for antiviral drugs.
Get a sneak peek at the antiviral drugs market dynamics @ Antiviral Drugs Market Dynamics Analysis
Report Metrics | Details |
Coverage | Global |
Study Period | 2019-2027 |
Base Year | 2021 |
Antiviral Drugs Market CAGR | ~4% |
Projected Antiviral Drugs Market Size by 2027 | USD 51.4 Billion |
Key Antiviral Drugs Companies | AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, among others |
Antiviral Drugs Market Assessment
- Antiviral Drugs Market Segmentation
- Market Segmentation By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Others
- Market Segmentation By Indication: HIV Infection, Herpes, Hepatitis, Influenza, and Others
- Market Segmentation By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and E-Commerce
- Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the antiviral drugs market are set to emerge as the trendsetter explore @ Antiviral Drugs Companies
Table of Contents
1 | Report Introduction |
2 | Executive summary |
3 | Regulatory and Patent Analysis |
4 | Key Factors Analysis |
5 | Porter's Five Forces Analysis |
6 | COVID-19 Impact Analysis on Antiviral Drugs Market |
7 | Antiviral Drugs Market Layout |
8 | Global Company Share Analysis - Key 3-5 Companies |
9 | Antiviral Drugs Market Company and Product Profiles |
10 | Project Approach |
11 | About DelveInsight |
Interested in knowing the antiviral drugs market by 2027? Click to get a snapshot of the Antiviral Drugs Market Trends
Related Reports
Influenza A Infections Pipeline
Influenza A Infections Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A infections companies, including Janssen Research & Development, LLC, Immune Targeting Systems Ltd, Vir Biotechnology, Inc., Guangdong Raynovent Biotech Co., Ltd, Hualan Biological Bacterin Co. Ltd., Celltrion, among others.
Influenza B Infections Pipeline
Influenza B Infections Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza B infections companies, including Leyden Labs, Nanjing Zenshine Pharmaceuticals, SAB Biotherapeutics, among others.
Influenza Pipeline
Influenza Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osiva, among others.
Seasonal Influenza Market
Seasonal Influenza Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key seasonal influenza companies, including SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., among others.
Influenza A Virus H5N1 Subtype Pipeline
Influenza A Virus H5N1 Subtype Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A virus H5N1 subtype companies, including Protein Sciences, Altimmune, Vaxart, Greffex, Cocrystal Pharma, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease MarketNeoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast-by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/the-global-antiviral-drugs-market-to-exhibit-growth-at-a-paltry-cagr-of-4-by-2027--delveinsight-301737007.html
